How do you pay?
Which strength? Pick yours
How many tablets?

How to pay the least

From

$8 a month, any strength

Generic lovastatin from Rx Outreach, by mail

What to do

  1. Make a free account on rxoutreach.org. Ask your prescriber to send the prescription there, or Rx Outreach can transfer it.Open Rx Outreach 
  2. Order generic lovastatin. It comes by mail.

Other ways

Need it today? From $13.84 for 30 tablets with the free Team Cuban Card, at pharmacies that take it. Get the free card and show it there.

See the price and get the card 

Every company’s lovastatin is rated by the FDA to work the same, so any pharmacy can fill your prescription with the one it stocks.

See every pharmacy’s price

Where to buy it

Pharmacies’ own cash prices for generic lovastatin, lowest first.

Pick up in storeDelivered

From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.

About these prices

Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.

Who makes it

4 companies sell lovastatin in this form, each one rated by the FDA as a substitute for the others. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.

  • BluePoint Laboratories10 mg, 20 mg, 40 mg

    Has lactose · Has dyes: D&C Yellow No. 10, FD&C Blue No. 2, FD&C Blue No. 1 · Made by Lupin Pharmaceuticals

    How it looks, what’s in it, NDCs

    10 mg Light green, oval, 6 mm, marked “LU / G01”

    PackageNDC
    Bottle of 10068001-314-00
    Bottle of 100068001-314-08

    20 mg Light green, round, 6 mm, marked “LU / G02”

    PackageNDC
    Bottle of 10068001-315-00
    Bottle of 100068001-315-08

    40 mg Light green, round, 8 mm, marked “LU / G03”

    PackageNDC
    Bottle of 10068001-316-00
    Bottle of 100068001-316-08

    Inactive ingredients: butylated hydroxyanisole, D&C Yellow No. 10, FD&C Blue No. 2, microcrystalline cellulose, lactose monohydrate, magnesium stearate, starch, corn, anhydrous lactose, FD&C Blue No. 1

    FDA label

  • Carlsbad Technology10 mg, 20 mg, 40 mg

    Has lactose

    How it looks, what’s in it, NDCs

    10 mg WHITE, round, 6 mm, marked “CTI / 141”

    PackageNDC
    Bottle of 6061442-141-60
    Bottle of 10061442-141-01
    Bottle of 50061442-141-05
    Bottle of 100061442-141-10

    20 mg WHITE, round, 8 mm, marked “CTI / 142”

    PackageNDC
    Bottle of 6061442-142-60
    Bottle of 10061442-142-01
    Bottle of 50061442-142-05
    Bottle of 100061442-142-10

    40 mg WHITE, round, 10 mm, marked “CTI / 143”

    PackageNDC
    Bottle of 6061442-143-60
    Bottle of 10061442-143-01
    Bottle of 50061442-143-05
    Bottle of 100061442-143-10

    Inactive ingredients: lactose monohydrate, magnesium stearate, cellulose, microcrystalline, poloxamer 188, sodium starch glycolate type a potato, starch, corn, talc, butylated hydroxyanisole

    FDA label

  • Lupin Pharmaceuticals10 mg, 20 mg, 40 mg

    Has lactose · Has dyes: D&C Yellow No. 10, FD&C Blue No. 2, FD&C Blue No. 1

    How it looks, what’s in it, NDCs

    10 mg Light green, oval, 6 mm, marked “LU / G01”

    PackageNDC
    Bottle of 6068180-467-07
    Bottle of 9068180-467-09
    Bottle of 10068180-467-01
    Bottle of 100068180-467-03

    20 mg Light green, round, 6 mm, marked “LU / G02”

    PackageNDC
    Bottle of 6068180-468-07
    Bottle of 10068180-468-01
    Bottle of 100068180-468-03
    Bottle of 500068180-468-05

    40 mg Light green, round, 8 mm, marked “LU / G03”

    PackageNDC
    Bottle of 6068180-469-07
    Bottle of 10068180-469-01
    Bottle of 100068180-469-03
    Bottle of 500068180-469-05

    Inactive ingredients: anhydrous lactose, butylated hydroxyanisole, D&C Yellow No. 10, FD&C Blue No. 2, cellulose, microcrystalline, lactose monohydrate, magnesium stearate, starch, corn, FD&C Blue No. 1

    FDA label

  • Teva Pharmaceuticals10 mg, 20 mg, 40 mg

    Has lactose · Has dyes: FD&C Yellow No. 6, FD&C Blue No. 1 aluminum lake, D&C Yellow No. 10 aluminum lake

    How it looks, what’s in it, NDCs

    10 mg Light Peach, round, 9 mm, marked “926 / TEVA”

    PackageNDC
    Bottle of 600093-0926-06
    Bottle of 10000093-0926-10

    20 mg Light Blue, round, 9 mm, marked “576 / TEVA”

    PackageNDC
    Bottle of 600093-0576-06
    Bottle of 10000093-0576-10

    40 mg Light Green, round, 9 mm, marked “928 / TEVA”

    PackageNDC
    Bottle of 600093-0928-06
    Bottle of 10000093-0928-10

    Inactive ingredients: lactose monohydrate, magnesium stearate, cellulose, microcrystalline, starch, corn, butylated hydroxyanisole, FD&C Yellow No. 6, FD&C Blue No. 1 aluminum lake, D&C Yellow No. 10 aluminum lake

    FDA label

Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.

What to say at the pharmacy

“Before you fill it, what would I pay for generic lovastatin?”

Paying cash? Ask for the cash price. With insurance, ask what your plan charges.

What it’s used for

What the FDA label says

Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.

Primary Prevention of Coronary Heart Disease

In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of:

  • Myocardial infarction
  • Unstable angina
  • Coronary revascularization procedures

(See CLINICAL PHARMACOLOGY, Clinical Studies.)

Coronary Heart Disease

Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.

Hypercholesterolemia

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.

Lipid Elevaions

Type · Lipoproteins elevated · major · minor

I · chylonicrons · TG · ↑→C

IIa · LDL · C · --

IIb · LDL, VLDL · C · TG

III · (rare) · IDL · C/TG · --

IV · VLDL · TG · ↑→C

V · (rare) · chylomicrons, VLDL · TG · ↑→C

IDL = intermediate-densit lipoprotein

Adolescent Patients with Heterozygous Familial Hypercholesterolemia

Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present:

  • LDL-C remains >189 mg/dL or
  • LDL-C remains >160 mg/dL and:
    • there is a positive family history of premature cardiovascular disease or
    • two or more other CVD risk factors are present in the adolescent patient

General Recommendations

Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation:

LDL-C = total-C - [0.2 × (TG) + HDL-C]

For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin is not indicated.

The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below:

Risk Category · LDL Goal (mg/dL) · LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) · LDL Level at Which to Consider Drug Therapy (mg/dL)

CHD† or CHD risk equivalents (10-year risk >20%) · <100 · ≥100 · ≥130 (100 to 129: drug optional) ††

2+ Risk factors (10 year risk ≤20%) · <130 · ≥130 · 10-year risk 10 to 20%: ≥130 10-year risk <10%: ≥160

0 to 1 Risk factor ††† · <160 · ≥160 · ≥190 (160 to 189: LDL-lowering drug optional)

† CHD, coronary heart disease

†† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory.

††† Almost all people with 0 to 1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.

After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category.

At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above).

Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy.

Although lovastatin may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). ***

The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below:

Category · Total-C (mg/dL) · LDL-C (mg/dL)

Acceptable · <170 · <110

Borderline · 170 to 199 · 110 to 129

High · ≥200 · ≥130

Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C.

Source: the FDA label for Lovastatin (Carlsbad Technology, Inc.), January 7, 2025. Full label on DailyMed 

Good to know

  • Different companies’ lovastatin can look different. The FDA requires each to work the same way.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.